BioCentury
ARTICLE | Finance

Altered Fate

Fate accepts IPO haircut, but now can reach Phase II inflection point

October 7, 2013 7:00 AM UTC

After spooking investors by disclosing a clinical delay in its S-1, Fate Therapeutics Inc. (NASDAQ:FATE) decided to accept a drastically reduced price from what it has been seeking in exchange for a public listing and enough cash to turn over some important cards.

Fate's lead product is ProHema, hematopoietic stem cells derived from umbilical cord blood that is modulated with FT1050, a small molecule prostaglandin E2 analog...